Safety outcomes of Alteplase among acute ischemic stroke patients with special characteristics
- 13 April 2007
- journal article
- research article
- Published by Springer Nature in Neurocritical Care
- Vol. 6 (3) , 181-185
Abstract
Although tissue plasminogen activator (tPA) has been approved for use in acute ischemic stroke, concerns linger regarding its safety. We analyzed whether patients in special subgroups (i.e., age >70 years, baseline National Institute of Health Stroke Scale (NIHSS) score >20, diabetes, congestive heart failure (CHF), and of Hispanic origin) have a higher risk of symptomatic intracerebral hemorrhage (SICH) than patients without these characteristics.Keywords
This publication has 19 references indexed in Scilit:
- Outcome and Severe Hemorrhagic Complications of Intravenous Thrombolysis With Tissue Plasminogen Activator in Very Old (≥80 Years) Stroke PatientsStroke, 2005
- Ethnic Disparities in StrokeStroke, 2005
- Tissue Plasminogen Activator for Acute Ischemic Stroke in Clinical PracticeStroke, 2003
- Risk Factors for Severe Hemorrhagic Transformation in Ischemic Stroke Patients Treated With Recombinant Tissue Plasminogen ActivatorStroke, 2001
- Intravenous Tissue Plasminogen Activator for Acute Ischemic Stroke in Patients Aged 80 Years and OlderStroke, 2000
- Thrombolysis With Intravenous rtPA in a Series of 100 Cases of Acute Carotid Territory StrokeStroke, 1998
- Differences in Stroke Between White, Hispanic, and Native American PatientsStroke, 1998
- Intracerebral Hemorrhage After Intravenous t-PA Therapy for Ischemic StrokeStroke, 1997
- Hemorrhagic Transformation in Acute Ischemic StrokeStroke, 1997
- Hemorrhagic transformation in cerebral embolism.Stroke, 1989